Andere talen BridgeBio Pharma, Inc.

Aandelen

BBIO

US10806X1028

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
24,95 ^USD	-0,12%		-12,02%	-38,20%

07/04	BridgeBio Pharma, Inc. Presenteert bewijs voor cardiale magnetische resonantie (CMR) beeldvorming consistent met klinische verbetering	CI
21/03	BRIDGEBIO PHARMA, INC. : JPMorgan Chase nog altijd een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	10/04
BridgeBio Pharma Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 study in Patients with Transthyretin Amyloid Cardiomyopathy	08/04
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	07/04
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	07/04
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	07/04
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	20/03
BridgeBio Pharma : BBIO – Encaleret for ADH1 – ACMG 2024 Genetic Testing	14/03
BridgeBio Pharma Prices $250 Million Stock Offering	06/03
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock	06/03
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	05/03
BridgeBio Pharma Commences $250 Million Share Offering	04/03
BridgeBio Pharma Announces Proposed Public Offering of Common Stock	04/03
BridgeBio Pharma Sells License for Potential Heart Disease Treatment to Bayer in Deal Worth up to $310 Million	04/03
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	04/03
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe	04/03
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	04/03
Bridgebio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	04/03
BridgeBio Pharma : BBIO – BBP-418 – MDA 2024 – Development of PROMIS Tool	01/03
BridgeBio Pharma : BBIO – BBP-418 – MDA 2024 – FORTIFY Phase 3 Trial Design	27/02
BridgeBio Pharma Q4 Loss Widens as Revenue Declines	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BridgeBio Pharma, Inc.

Aandelen

BBIO

US10806X1028

Andere talen

Filters